ALISON REGAN: Open Payments
NPI 1780425512 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$557 in 27 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $166 · 2025 $557
Food & beverage: $557
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $253 |
| Astellas Pharma US Inc | 4 | $131 |
| Novo Nordisk Inc | 2 | $38 |
| Seqirus USA Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| PFIZER INC. | 1 | $20 |
| Exact Sciences Corporation | 1 | $17 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: Veozah, QULIPTA, VRAYLAR, UBRELVY, ELIQUIS, Flucelvax, REXULTI, GARDASIL 9.
Industry payments across NE — which companies pay providers there.
